MedTrace Logo

Clinical Trials

NCT04236349 | COMPLETED
30 participants

Tuberculosis Cohort in the North of Paris

Study Type:
OBSERVATIONAL
Last Updated:
2026-08-11
Start Date:
2018-05-01
Completion:
2021-02-17
Conditions
  • Pulmonary Tuberculosis
  • Extra Pulmonary Tuberculosis
Interventions
  • GENETIC
No Results Yet
NCT04222413 | RECRUITING | PHASE1
116 participants

Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors

Study Type:
INTERVENTIONAL
Last Updated:
2026-08-11
Start Date:
2020-10-27
Completion:
2027-12-31
Conditions
  • Advanced Solid Tumors
  • Metastatic Pancreatic Cancer
  • Pediatric Solid Tumor
  • Advanced Breast Cancer
  • Malignant Peripheral Nerve Sheath Tumor
  • Colorectal Neoplasms
Interventions
  • DRUG
No Results Yet
NCT04208529 | ENROLLING_BY_INVITATION | PHASE3
160 participants

A Long-term Follow-up Study in Participants Who Received CTX001

Study Type:
INTERVENTIONAL
Last Updated:
2026-08-11
Start Date:
2021-01-20
Completion:
2039-09-30
Conditions
  • Beta-Thalassemia
  • Thalassemia
  • Sickle Cell Disease
  • Hematologic Diseases
  • Hemoglobinopathies
  • Genetic Diseases, Inborn
  • Sickle Cell Anemia
Interventions
  • BIOLOGICAL
No Results Yet
NCT04164082 | ACTIVE_NOT_RECRUITING | PHASE2
161 participants

Testing the Addition of an Anti-cancer Drug, Pembrolizumab, to the Usual Intravesical Chemotherapy Treatment (Gemcitabine) for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer

Study Type:
INTERVENTIONAL
Last Updated:
2026-08-11
Start Date:
2020-03-18
Completion:
2026-12-09
Conditions
  • Bladder Flat Urothelial Carcinoma In Situ
  • Non-Muscle Invasive Bladder Urothelial Carcinoma
  • Stage 0a Bladder Cancer AJCC v8
  • Stage 0is Bladder Cancer AJCC v8
  • Stage I Bladder Cancer AJCC v8
Interventions
  • PROCEDURE
  • DRUG
  • BIOLOGICAL
No Results Yet
NCT04092283 | ACTIVE_NOT_RECRUITING | PHASE3
660 participants

Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients With Unresectable Stage III Non-Small Cell Lung Cancer

Study Type:
INTERVENTIONAL
Last Updated:
2026-08-11
Start Date:
2020-04-29
Completion:
2028-12-31
Conditions
  • Recurrent Lung Non-Small Cell Carcinoma
  • Stage III Lung Cancer AJCC v8
  • Stage IIIA Lung Cancer AJCC v8
  • Stage IIIB Lung Cancer AJCC v8
  • Stage IIIC Lung Cancer AJCC v8
  • Unresectable Lung Non-Small Cell Carcinoma
Interventions
  • DRUG
  • BIOLOGICAL
No Results Yet
NCT03866382 | RECRUITING | PHASE2
314 participants

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

Study Type:
INTERVENTIONAL
Last Updated:
2026-08-11
Start Date:
2019-05-13
Completion:
2027-02-28
Conditions
  • Bladder Adenocarcinoma
  • Bladder Clear Cell Adenocarcinoma
  • Bladder Mixed Adenocarcinoma
  • Bladder Neuroendocrine Carcinoma
  • Bladder Small Cell Neuroendocrine Carcinoma
  • Bladder Squamous Cell Carcinoma
  • Chromophobe Renal Cell Carcinoma
  • Collecting Duct Carcinoma
  • Invasive Bladder Giant Cell Urothelial Carcinoma
  • Invasive Bladder Lymphoepithelioma-Like Carcinoma
  • Invasive Bladder Nested Urothelial Carcinoma
  • Invasive Bladder Plasmacytoid Urothelial Carcinoma
  • Invasive Bladder Sarcomatoid Urothelial Carcinoma
  • Invasive Bladder Urothelial Carcinoma
  • Kidney Medullary Carcinoma
  • Large Cell Neuroendocrine Carcinoma
  • Malignant Testicular Leydig Cell Tumor
  • Malignant Testicular Sertoli Cell Tumor
  • Metastatic Bladder Carcinoma
  • Metastatic Bladder Clear Cell (Glycogen-Rich) Urothelial Carcinoma
  • Metastatic Bladder Giant Cell Urothelial Carcinoma
  • Metastatic Bladder Large Cell Neuroendocrine Carcinoma
  • Metastatic Bladder Lipid-Rich Urothelial Carcinoma
  • Metastatic Bladder Micropapillary Urothelial Carcinoma
  • Metastatic Bladder Plasmacytoid Urothelial Carcinoma
  • Metastatic Bladder Sarcomatoid Urothelial Carcinoma
  • Metastatic Bladder Small Cell Neuroendocrine Carcinoma
  • Metastatic Bladder Squamous Cell Carcinoma
  • Metastatic Chromophobe Renal Cell Carcinoma
  • Metastatic Kidney Medullary Carcinoma
  • Metastatic Malignant Genitourinary System Neoplasm
  • Metastatic Papillary Renal Cell Carcinoma
  • Metastatic Penile Carcinoma
  • Metastatic Prostate Small Cell Neuroendocrine Carcinoma
  • Metastatic Sarcomatoid Renal Cell Carcinoma
  • Metastatic Urethral Carcinoma
  • Papillary Renal Cell Carcinoma
  • Sarcomatoid Renal Cell Carcinoma
  • Stage IV Bladder Cancer AJCC v8
  • Stage IV Penile Cancer AJCC v8
  • Stage IV Renal Cell Cancer AJCC v8
  • Stage IV Urethral Cancer AJCC v8
  • Stage IVB Prostate Cancer AJCC v8
  • Urachal Adenocarcinoma
  • Urethral Clear Cell Adenocarcinoma
Interventions
  • PROCEDURE
  • DRUG
  • BIOLOGICAL
No Results Yet
NCT03660826 | ACTIVE_NOT_RECRUITING | PHASE2
288 participants

Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone

Study Type:
INTERVENTIONAL
Last Updated:
2026-08-11
Start Date:
2018-09-27
Completion:
2024-12-06
Conditions
  • Endometrial Adenocarcinoma
  • Endometrial Mixed Cell Adenocarcinoma
  • Endometrial Serous Adenocarcinoma
  • Endometrial Undifferentiated Carcinoma
  • Endometrioid Adenocarcinoma
  • Stage IV Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8
Interventions
  • PROCEDURE
  • DRUG
  • BIOLOGICAL
Results Available
Previous
Sorted by latest updates
Next
Showing 40 trials per page